NMPA Accepts the NDA for Luye Pharma’s Ruoxinlin® for the New Indication of Generalized Anxiety Disorder
Shanghai, January 8, 2026 — Luye Pharma Group today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for Ruoxinlin® (Toludesvenlafaxine Hydrochloride ...
January 08,2026
Luye Pharma Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Injectable Antipsychotics in the Chinese Mainland
Shanghai, December 24th, 2025 -- Luye Pharma Group announced that it has entered into an agreement with Jiangsu Nhwa Pharmaceutical Co., Ltd. (Nhwa) granting the latter the exclusive rights to commercialize Rykindo (risperidone microspheres for injection (Ⅱ)), Ruibailai (paliperidone ...
December 24,2025
07
2025-12
Luye Pharma’s Five New Products Included in China’s 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug List
24
2025-11
Luye Pharma Receives FDA Clearance of IND Application for Its Next-generation 5-HT2AR Inverse Agonist/5-HT2CR Antagonist LY03017
28
2025-08
Luye Pharma Announces 2025 Half-Year Results
18
2025-08
All Patients Enrolled for the Phase III Clinical Trial of Luye Pharma’s Ruoxinlin® for Treating Generalized Anxiety Disorder
03
2025-08
First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma’s Investigational Antidepressant Targeting NET/DAT/GABAAR
10
2025-04
Luye Pharma Launches Its Transdermal Patch Rotigotine Luye in the UK for the Treatment of Parkinson’s Disease and Restless Legs Syndrome
07
2025-04
Luye Pharma’s Class 1 Innovative Antidepressant Ruoxinlin® Approved for Marketing in Macao
07
2025-04
Luye Pharma Announces U.S. Launch of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder
31
2025-03
Luye Pharma’s Rivastigmine Twice Weekly Transdermal Patch Approved for Marketing in Japan for the Treatment of Alzheimer’s Dementia
14
2025-01
Luye Pharma’s Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in the U.S.
